Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,976.00
Bid: 1,976.00
Ask: 1,977.00
Change: 16.00 (0.82%)
Spread: 1.00 (0.051%)
Open: 1,994.00
High: 2,000.00
Low: 1,959.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Earnings, Trading Statements Calendar - Next 7 Days

Wed, 07th Mar 2018 16:11

Thursday March 8 
G4SFull Year Results
AvivaFull Year Results
CountrywideFull Year Results
ATTRAQTFull Year Results
Origin EnterprisesHalf Year Results
John Lewis PartnershipFull Year Results
Domino's Pizza GroupFull Year Results
Capital & RegionalFull Year Results
CommunisisFull Year Results
Impellam GroupFull Year Results
Premier OilFull Year Results
Alliance TrustFull Year Results
Alfa Financial SoftwareFull Year Results
Spirent CommunicationsFull Year Results
TT ElectronicsFull Year Results
BioPharma CreditFull Year Results
Friday 9 March 
SIGFull Year Results
InmarsatFull Year Results
GVC HoldingsFull Year Results
Monday 12 March 
ClarksonFull Year Results
Medica GroupFull Year Results
Hutchison China MeditechFull Year Results
Polymetal InternationalFull Year Results
Global Ports HoldingFull Year Results
Tuesday 13 March 
AntofagastaFull Year Results
TP ICAPFull Year Results
Cairn EnergyFull Year Results
BangoFull Year Results
Midwich GroupFull Year Results
Stadium GroupFull Year Results
Goal Soccer CentresFull Year Results
XLMediaFull Year Results
Fevertree DrinksFull Year Results
John MenziesFull Year Results
RestoreFull Year Results
Non-Standard FinanceFull Year Results
Seeing MachinesHalf Year Results
LMS CapitalFull Year Results
CrossriderFull Year Results
Surgical InnovationsFull Year Results
ApplegreenFull Year Results
ComputacenterFull Year Results
Close Brothers GroupFull Year Results
Gresham TechnologiesFull Year Results
ZotefoamsFull Year Results
Baillie Gifford Shin NipponFull Year Results
H&T GroupFull Year Results
French Connection GroupFull Year Results
Smart Matering SystemsFull Year Results
Wednesday 14 March 
PrudentialFull Year Results
DignityFull Year Results
Brooks MacdonaldHalf Year Results
WM Morrison SupermarketsFull Year Results
Balfour BeattyFull Year Results
Charles TaylorTrading Statement 
Burfod CapitalFull Year Results
Hikma PharmaceuticalsFull Year Results
MarshallsFull Year Results
EMIS GroupFull Year Results
ForterraFull Year Results
Advanced Medical Solutions GroupFull Year Results
Safecharge InternationalFull Year Results
NorthamberHalf Year Results
  

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.